Published in Hepatitis Weekly, February 20th, 2006
In vitro studies demonstrate a sustained release of the active ingredient over a 6-hour period. The study results were reported by Skinvisible at the Retroscreen Virology conference, "Bird Flu: The First Pandemic of the 21st Century," at St. Bartholomew's Hospital, London.
The active ingredient in Skinvisible's product is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.